United States Respiratory Syncytial Virus (RSV) Therapeutics Market 2025 | Emerging Opportunities & Competitive Landscape Analysis

Global Respiratory Syncytial Virus (RSV) Therapeutics Market reached USD 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 2.4 billion by 2030. The market is expected to exhibit a CAGR of 10.2% during the forecast period (2024-2031).

DataM Intelligence has published a new research report on "Respiratory Syncytial Virus Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

United States: Recent Industry Developments
✅ October 2025: Pfizer launched a new RSV vaccine targeting infants and elderly populations to reduce hospitalization rates.
✅ September 2025: Regeneron Pharmaceuticals announced promising results from clinical trials of monoclonal antibody therapies for RSV prevention.
✅ August 2025: The CDC updated RSV treatment guidelines emphasizing early diagnosis and integrated care protocols.

Japan: Recent Industry Developments
✅ October 2025: Daiichi Sankyo introduced an RSV prophylactic treatment approved for high-risk infants.
✅ September 2025: Collaborative research focused on developing next-generation RSV vaccines leveraging mRNA technology.
✅ August 2025: Increased government funding supported awareness campaigns to prevent RSV outbreaks in childcare centers.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/respiratory-syncytial-virus-market?kb

The average cost per dose of palivizumab ranges from $1,660 for infants under 6 months to $2,500 for children in their second year. Immunoprophylaxis with palivizumab costs approximately $302,000 to prevent one RSV-related hospitalization in preterm infants under 6 months without other risk factors.

By 2030, one in six people globally will be aged 60 or older, with the 60+ population rising from 1 billion in 2020 to 1.4 billion. By 2050, the number of older adults is expected to double worldwide.

Vaccine Introductions

Beyfortus (nirsevimab), a monoclonal antibody for infant RSV prophylaxis, has been rolled out in over a dozen countries in Europe and North America, significantly reducing RSV hospitalizations.​

Novel mRNA and protein subunit vaccine candidates targeting multiple RSV strains are entering late-stage development, potentially expanding protection to elderly and adult populations.

Key Players:

Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience

Latest M&A Activity

Pharmaceutical giants like Pfizer, Sanofi, and AstraZeneca have engaged in strategic partnerships and licensing agreements to advance RSV vaccine and monoclonal antibody portfolios.

Intense competition to acquire or license innovative RSV assets continues to drive consolidation in the pharmaceutical and biotech sectors, although no massive blockbuster M&A deals specifically for RSV were reported in this short period.

Growth Forecast Projected:

The Global Respiratory Syncytial Virus Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Respiratory Syncytial Virus Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=respiratory-syncytial-virus-market?kb

Key Segments:

By Drug Type: (Ribavirin, Nirsevimab, Virazole, Palivizumab, Riba Tab, Others)

By Dosage Form: (Oral, Injectable, Inhaler, Others)

By Treatment Type: (Immune prophylaxis, Supportive care, Antiviral Medications)

By Distribution Channel: (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Recent FDA Approvals

Merck's ENFLONSIATM (clesrovimab-cfor), a long-acting monoclonal antibody for prevention of RSV lower respiratory tract disease in neonates and infants, was approved by the FDA in November 2025. ENFLONSIA demonstrated an 84.3% reduction in RSV-related hospitalizations through 5 months post-administration.​

Existing vaccines like GSK's Arexvy and Pfizer's Abrysvo continue strong market performance with regulatory clearances for older adults and immunocompromised populations.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Respiratory Syncytial Virus producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Respiratory Syncytial Virus revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/respiratory-syncytial-virus-market?kb

Latest Clinical Trials

Traws Pharma completed Phase 1 clinical trials for tivoxavir marboxil, a single-dose oral antiviral candidate targeting H5N1 avian influenza and RSV infections, showing promising safety and pharmacokinetic profiles.​

Multiple phase II and III clinical trials are underway testing vaccine candidates targeting RSV prefusion F protein (RSVPreF3) in maternal immunization to protect infants, showing greater than 80% efficacy in preventing severe RSV lower respiratory tract disease.​

Intranasal vaccine candidates are progressing through early-phase trials, aiming for broader mucosal immunity and ease of administration to infants and high-risk adults

Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.